STEADYMED LTD. INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations
August 31 2017 - 6:23PM
Business Wire
Girard Gibbs LLP is investigating claims on behalf of investors
of SteadyMed Ltd. (NASDAQ: STDY) regarding possible violations of
federal securities laws following the FDA’s refusal to review the
company’s new drug application for Trevyent.
To speak privately with an attorney regarding this class
action lawsuit investigation, click here.
On August 31, 2017, SteadyMed announced that it had received a
Refusal to File letter from the FDA regarding the company’s New
Drug Application for Trevyent, a treatment for pulmonary arterial
hypertension. Specifically, the FDA determined, based on a
preliminary review of the New Drug Application, that it was not
complete enough to permit a substantive review. According to
SteadyMed, the FDA requested additional information on certain
device specifications and performance testing as well as additional
design verification and validation testing on the final Trevyent
product.
Following this news, SteadyMed’s share price plummeted by more
than 44% in intraday trading, to ultimately close down more than
35% at $3.80 on August 31, 2017.
If you purchased or acquired shares of SteadyMed and would like
to speak privately with a securities attorney to learn more about
the investigation and your legal rights, visit our website or
contact the securities team directly at (800) 254-9493.
Girard Gibbs LLP is one of the nation’s leading firms
representing individual and institutional investors
in securities litigation to correct abusive corporate
governance practices, breaches of fiduciary duty, and proxy
violations. The firm has recovered over a billion dollars for its
clients against some of the world’s largest corporations, and has
earned Tier-1 rankings and been named in the U.S. Lawyers –
Best Law Firms list for five consecutive years.
This press release may constitute Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170831006480/en/
Girard Gibbs LLPEileen Epstein,
510-350-9728eje@classlawgroup.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Sep 2024 to Oct 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Steadymed Ltd. - Ordinary Shares (delisted) (NASDAQ): 0 recent articles
More Steadymed Ltd. - Ordinary Shares (MM) News Articles